The BRAAVE2020 study investigated the efficacy of switching Black Americans living with HIV to a B/F/TAF single-pill regimen.

A flexible silicone ring that slowly releases antiretrovirals is one of just two long-acting HIV prevention products ...

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

for its Abbreviated New Drug Application for Raltegravir Tablets USP, 600 mg. Raltegravir Tablets USP, 600 mg are indicated ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

For years, a preventive treatment that can significantly decrease the risk of contracting HIV has been available in Nova ...

as it can significantly reduce new infections of HIV. 2 However, ADR and transmitted drug resistance (TDR) are possible given the encouragement to begin ART early. An increased number of countries ...

Studies from around the world consistently find that the number of new HIV cases falls when this is done ... though she ...

New analyses highlight use of long-acting injectable Vocabria Rekambys (cabotegravir rilpivirine LA) in clinical trial and real-world populations, and the economic and public health impact ...

The country’s successful rollout of HIV anti-retroviral drugs has lulled many into a false sense of security around ...